Schmidt E - Search Results

1

S2k-Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: 2019 Update.

Schmidt E, Sticherling M, Sárdy M, Eming R, Goebeler M, Hertl M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, Nast A, Orzechowski HD, Pfeiffer C, Schuster V, Sitaru C, Zidane M, Zillikens D, Worm M. Schmidt E, et al. J Dtsch Dermatol Ges. 2020 May;18(5):516-527. doi: 10.1111/ddg.14097_g. J Dtsch Dermatol Ges. 2020. PMID: 32413222 German. No abstract available.

2

High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid.

Schmidt E, Bröcker EB, Zillikens D. Schmidt E, et al. Arch Dermatol. 1995 Aug;131(8):966-7. Arch Dermatol. 1995. PMID: 7632081 No abstract available.

3

Elevated levels of interleukin-8 in blister fluid of bullous pemphigoid compared with suction blisters of healthy control subjects.

Schmidt E, Ambach A, Bastian B, Bröcker EB, Zillikens D. Schmidt E, et al. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):310-2. doi: 10.1016/s0190-9622(96)80146-0. J Am Acad Dermatol. 1996. PMID: 8642104 No abstract available.

4

Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid.

Schmidt E, Bastian B, Dummer R, Tony HP, Bröcker EB, Zillikens D. Schmidt E, et al. Arch Dermatol Res. 1996 Jun;288(7):353-7. doi: 10.1007/BF02507102. Arch Dermatol Res. 1996. PMID: 8818181

5

Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.

Zillikens D, Caux F, Mascaro JM, Wesselmann U, Schmidt E, Prost C, Callen JP, Bröcker EB, Diaz LA, Giudice GJ. Zillikens D, et al. Among authors: schmidt e. J Invest Dermatol. 1999 Jul;113(1):117-21. doi: 10.1046/j.1523-1747.1999.00618.x. J Invest Dermatol. 1999. PMID: 10417629 Free article.

6

Antiepiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases?

Leverkus M, Schmidt E, Lazarova Z, Bröcker EB, Yancey KB, Zillikens D. Leverkus M, et al. Among authors: schmidt e. Arch Dermatol. 1999 Sep;135(9):1091-8. doi: 10.1001/archderm.135.9.1091. Arch Dermatol. 1999. PMID: 10490114

7

[Immunopathologic changes in 115 patients with bullous pemphigoid].

Kippes W, Schmidt E, Roth A, Rzany B, Bröcker EB, Zillikens D. Kippes W, et al. Among authors: schmidt e. Hautarzt. 1999 Dec;50(12):866-72. doi: 10.1007/s001050051001. Hautarzt. 1999. PMID: 10663021 German.

8

Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.

Schmidt E, Obe K, Bröcker EB, Zillikens D. Schmidt E, et al. Arch Dermatol. 2000 Feb;136(2):174-8. doi: 10.1001/archderm.136.2.174. Arch Dermatol. 2000. PMID: 10677092 Clinical Trial.

9

IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.

Döpp R, Schmidt E, Chimanovitch I, Leverkus M, Bröcker EB, Zillikens D. Döpp R, et al. Among authors: schmidt e. J Am Acad Dermatol. 2000 Apr;42(4):577-83. J Am Acad Dermatol. 2000. PMID: 10727301

10

[Pemphigus. Loss of desmosomal cell-cell contact].

Schmidt E, Bröcker EB, Zillikens D. Schmidt E, et al. Hautarzt. 2000 May;51(5):309-18. doi: 10.1007/s001050051124. Hautarzt. 2000. PMID: 10875067 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,886 results

Search Page